Skip to Main Content
Pitt Home
Find People
School of Medicine
Toggle navigation
Skip Navigation Links
Home
About
Leadership
Mission
Department Statistics
Building Information
Thomas E. Starzl BST
Biomedical Science Tower 3
Conference Rooms
BSTWR E1347 - Wingard/Lazo Conference Room
BSTWR 1395
Shops
Cell Biology/Pharmacology Machine Shop
Directory
Primary Faculty
Secondary Faculty
Graduate Students
Fellows
Administrative Staff
Research Staff
Adjunct Faculty
Department Alumni
Research
Research Areas
Labs
Equipment
Non-PC&B Personnel Core Facilities Access Request
Funding Opportunities
Faculty Development Program
Responsible Conduct of Research
Education
Molecular Pharmacology Graduate Program
Current Students
Current Student Roster
Student Publications
Diversity, Accessibility, and Counseling
Student Awards
MPGP News
Student Poster and Presentation Resources
Prospective Students
Welcome from the Director
Research Opportunities
PhD Track
MD/PhD Track
Financial Aid
Graduate Faculty
Admin Staff
Graduate Courses
Lab Rotations
Events
Grad Student Event Calendar
Graduate Student Event Schedule
Alumni/Career Development
Alumni
Alumni Contacts
Molecular Pharmacology Facebook Group
Molecular Pharmacology Student-Alumni Network (LinkedIn)
SOM Graduate Studies - Career and Professional Development
Executive Committee
Student Testimonials
IBGP
Funding Opportunities
NIH T32 Training Grant
Outcomes
Predoctoral Fellowship
Admissions
Student Handbook & General Timeline
Links
Useful Links
School of Medicine
PubMed
Remote Resources
Biomedical Masters Program
Undergraduate Research
Summer Fellowships
Lab Rotations
Graduate Fellowships
News
Events
Calendar
Seminar Series
Links
Contact
Opportunities
Department
PORtal
Computer Resources Access Request
IT-Equipment-Facilities Support Request
Poster Requests
Reservation Calendars
Badge Access Request
Home
>
Directory
>
Primary Faculty
>
Stevan P. Tofovic, MD, PhD
Stevan P. Tofovic, MD, PhD
Associate Professor
100 Technology Drive, Bridgeside Point Building I, Room 542
Bridgeside Point Building I, Room 542
Pittsburgh, PA 15219
tofovic@pitt.edu
Phone: 412-648-3363
Fax: 412-624-5070
Education
MD, University of Skopje School of Medicine, Yugoslavia, 1979
MS (Pharmacology), University of Skopje School of Medicine, Yugoslavia, 1984
PhD (Pharmacology), University of Skopje School of Medicine, Republic of Macedonia, 1992
Postdoctoral Fellowship (Clinical Pharmacology), Vanderbilt University School of Medicine, 1989
Research Details
Publications
Awards, Honors, and Sponsored Research
Research Areas
Cardiovascular and Renal Pharmacology
Clinical Pharmacology
Hormone Pharmacology
Metabolic Syndrome Pharmacology
Pulmonary Pharmacology
Dr. Tofovic has had a sustained interest in the development and characterization of complex animal models of cardiovascular and renal disease, with primary focus on pulmonary hypertension (PH), heart failure and diabetic nephropathy. Using these model systems, he studies the underlining pathophysiology of cardiovascular/renal diseases and evaluates new therapeutic modalities. His lab is one of the few laboratories in the country that are studying the effects of gender and estradiol metabolism on the development and progression of PH. More recent studies are related to (1) the effects of sex and sex hormones and their metabolites on development of HFpEF and (2) the role of purine metabolism in PH with focus on hemolysis-induced pulmonary vasculopathy and PH.
Role purine nucleoside phosphorylase (PNPase) in development of angioproliferative vasculopathy and hemolytic angioproliferative pulmonary hypertension (HA-PH)
In sickle cell disease endothelial purine nucleoside phosphorylase (PNPase) activity stimulates angioproliferation and promotes the development of HA-PH. Further, in hemolytic states red blood cell -derived extracellular PNPase acts in concert with xanthine oxidase and guanase and the net effects of these three enzymes lead to changes in the guanosine-inosine metabolome that favor hemolytic vasculopathy and HA-PH (
Figure 1
).
Figure 2.
When superimposed on endothelial injury induced by VEGF receptor antagonist SU5416, chronic treatment with hemolyzed autologous blood (HAB) leads to development of angioproliferative PH. Occlusive [
A
] and plexiform (PLX) lesions [
C]
and neomuscularization of small-size pulmonary arteries [
B
] in rats treated with either Sugen 5416 (SU Day 26) or Sugen 5416+ 10 days of HAB treatment (Group SU+HAB Day 26). The combination treatment resulted in development of numerous occlusive lesions in small-size (<50?m) pulmonary arteries [
A
] and formation of PLX lesions [
D-F
] similar to those seen in Sugen+hypoxia model [
G
].
Role of estradiol metabolism in PAH
.
A
, Activities of 2-hydroxylation, 16
a
-hydroxylation, and 17
b
-HSD pathways determine the overall biological effects of estradiol (E2) in PAH.
B
, In ECs, 2-methoxyestradiol (2ME) is a more potent modulator of prostacyclin, endothelin, and nitric oxide synthesis/release than (E2); 2ME and E2 have opposite effects on endothelial pathobiology in PAH (2HE, 2-hydroxyestradiol; 2ME1,2-methoxyestrone; E3, estriol; 16
a
E1, 16
a
-estrone).
Rescue treatment with estradiol (day 10-21) exacerbates PH formation of occlusive and plexiform lesions in OVX female rats with SU5416+hypoxia-induced PAH. In contrast, preventive treatment with 2-ME abolishes development of angioproliferative lesions and reduces PH induced by SU5416.
Journal Articles
Bilan V, Schneider F, Novelli EM, Kelley EE, Sriva S, Gladwin M, Jackson EK and
Tofovic SP
. EXPRESS: Experimental Intravascular Hemolysis Induces Hemodynamic and Pathological Pulmonary Hypertension - Association with Accelerated Purine Metabolism. Pulm Circ 8:2045894018791557, 2018.
Salah EM, Bastacky SI, Jackson EK and
Tofovic SP
. Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction. J Cardiovasc Pharmacol 71:205-214, 2018.
Rafikova O, Srivastava A, Desai AA, Rafikov R and
Tofovic SP
. Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung. Respir Res 19:69, 2018.
Goncharov DA, Goncharova EA,
Tofovic SP
, Hu J, Baust JJ, Pena AZ, Ray A, Rode A, Vanderpool RR, Mora AL, Gladwin MT and Lai YC. Metformin Therapy for Pulmonary Hypertension Associated with HFpEF versus PAH. Am J Respir Crit Care Med 198:681-684, 2018.
Hu J, Sharifi-Sanjani M and
Tofovic SP
. Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding. J Cardiovasc Pharmacol 69:93-100, 2017.
Tofovic SP
, Salah EM, Smits GJ, Whalley ET, Ticho B, Deykin A and Jackson EK. Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction. J Pharmacol Exp Ther 356:333-340, 2016.
Lai YC, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA, St Croix CM, Garcia-Ocana A, Goncharova EA,
Tofovic SP
, Mora AL and Gladwin MT. SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Circulation 133:717-731, 2016.
Rafikova O, Rafikov R, Kumar S, Sharma S, Aggarwal S, Schneider F, Jonigk D, Black SM and
Tofovic SP
. Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med 56:28-43, 2013.
Bilan VP, Salah EM, Bastacky S, Jones HB, Mayers RM, Zinker B, Poucher SM and
Tofovic SP
. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol 210:293-308, 2011.
Sponsored Research
Role of Cardiac and Renal DPP4 - 4/1/2017 - 3/31/2021
NIH - R01HL069846